Back


31/07/2019
Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate
Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases. [...]

Download the pdf file





X

X